NeuroSense Granted Brazilian Patent Covering PrimeC Composition

Rhea-AI Summary

NeuroSense (NASDAQ: NRSN) announced that Brazil’s INPI granted Patent No. BR 112024007727-6 for its PrimeC composition, providing protection through October 2042. The grant follows corresponding U.S. (12,097,185) and Australian (2022370513) patents, strengthening the company’s global IP estate.

PrimeC is a fixed-dose oral combination of ciprofloxacin and celecoxib in an extended-release formulation. NeuroSense is preparing to initiate a Phase 3 pivotal PARAGON trial in ALS after positive Phase 2b PARADIGM results and FDA clearance, supporting longer-term development and potential commercialization.

Positive

• Brazilian patent extends protection through October 2042
• Composition-of-matter protection secured in Brazil
• Corresponding patents in U.S. and Australia
• Preparing for Phase 3 PARAGON after positive Phase 2b

Negative

• None.

News Market Reaction – NRSN

-8.19%

5 alerts

-8.19% Session close to close

-6.1% Trough in 41 min

$28.35M Market Cap

0.8x Rel. Volume

In the Apr 6 session, NRSN declined 8.19%, reflecting a notable negative market reaction. Argus tracked a trough of -6.1% from its starting point during tracking. Our momentum scanner triggered 5 alerts that day, indicating moderate trading interest and price volatility.

Data tracked by StockTitan Argus on the day of publication.

Market Context

The stock moved -8.2% in the session following this news. A negative reaction despite positive news ...

Analysis

The stock moved -8.2% in the session following this news. A negative reaction despite positive news would have fit prior patterns where favorable PrimeC updates sometimes met selling pressure. The Brazilian patent extends protection to October 2042, reinforcing the IP position, yet the stock previously saw declines after supportive clinical and regulatory milestones. With shares already below the $1.18 200-day MA and well under the $2.60 52-week high, sentiment around financing needs under the $150,000,000 shelf could also weigh on reactions.

Key Figures

Shelf registration size: $150,000,000 ATM program size: $6,525,000 Unsold prior shelf: $85,778,066 +5 more

8 metrics

Shelf registration size $150,000,000 Form F-3 base shelf filed 2026-01-29

ATM program size $6,525,000 Capital on Demand at-the-market under F-3 shelf

Unsold prior shelf $85,778,066 Carried forward from prior F-3

Brazilian patent expiry October 2042 Patent protection for PrimeC composition in Brazil

Brazilian patent number BR 112024007727-6 Patent covering PrimeC composition in Brazil

U.S. patent number 12,097,185 Corresponding U.S. patent for PrimeC composition

Australian patent number 2022370513 Corresponding Australian patent for PrimeC composition

Planned trial phase Phase 3 PARAGON pivotal clinical trial in ALS for PrimeC

Historical Context

5 past events · Latest: Mar 31 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Mar 31	Earnings and update	Positive	+3.3%	Year-end results plus PrimeC Phase 3 clearance and survival data update.
Mar 24	Regulatory milestones	Positive	-1.5%	Regulatory and clinical progress update, including rescheduled Health Canada meeting.
Mar 18	Conference data	Positive	-5.4%	Announcement of new PrimeC ALS data presentation at AD/PD 2026.
Mar 18	Release correction	Neutral	-5.4%	Correction notice related to prior PrimeC AD/PD 2026 presentation release.
Mar 16	Phase 2b results	Positive	+1.4%	JAMA Neurology publication of PARADIGM Phase 2b ALS results for PrimeC.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent news on PrimeC and regulatory milestones has often been positive, yet price reactions were mixed, with several supportive updates followed by flat or negative moves.

Recent Company History

Over recent months, NRSN has repeatedly highlighted progress for PrimeC in ALS, including Phase 2b PARADIGM data, a JAMA Neurology publication, and FDA clearance for the Phase 3 PARAGON trial. Regulatory and clinical updates around conferences and milestone meetings have produced mixed stock reactions, with both gains and selloffs on ostensibly positive news. Today’s Brazilian patent grant further extends the PrimeC franchise as the company moves toward pivotal development and potential commercialization.

Key Terms

composition-of-matter, extended-release, als, alzheimer's disease, +4 more

8 terms

composition-of-matter regulatory

"Securing composition-of-matter protection in Brazil is another important step"

A composition-of-matter is a legal description of a specific chemical or biological substance or mixture—think of it as the exact recipe and ingredients that make up a drug, material, or chemical product. For investors, ownership of a composition-of-matter patent can act like a locked recipe that keeps competitors out, protecting future sales and profit margins and reducing the risk that a product will be easily copied.

extended-release medical

"a synchronized, extended-release formulation specifically targeted to deliver both agents"

Extended-release is a drug formulation designed to release its active ingredient slowly over an extended period so the medicine stays at steadier levels in the body and usually needs to be taken less often—think of a timed-release coffee versus sipping many short espressos. Investors care because extended-release versions can improve patient adherence, reduce side effects, and create product differentiation that supports higher pricing, longer commercial lifecycles, and clearer revenue visibility, while also attracting specific regulatory and manufacturing considerations.

als medical

"supporting the long-term development and potential commercialization of PrimeC in ALS"

Amyotrophic lateral sclerosis (ALS) is a progressive neurological disease that damages the nerve cells controlling muscles, gradually causing weakness, loss of movement and difficulty breathing — similar to the body’s wiring slowly failing. For investors, ALS matters because research progress, clinical trial results, regulatory approvals or setbacks can dramatically affect the value of companies developing treatments, patient-care markets and related healthcare services.

alzheimer's disease medical

"potential commercialization of PrimeC in ALS, Alzheimer's disease and additional"

A progressive brain disorder that slowly erodes memory, thinking and the ability to carry out daily tasks as nerve cells are damaged and lost; symptoms typically worsen over years and can lead to severe impairment. Investors care because it drives a large, growing market for diagnostics, treatments and care services, but also carries high scientific, regulatory and commercial risk—similar to developing a complex new product that must pass difficult safety tests before it can reach patients.

neuroinflammation medical

"disease pathways implicated in ALS, including neuroinflammation, iron dysregulation"

Neuroinflammation is the brain or spinal cord’s immune reaction to injury, infection, or abnormalities, where cells and molecules become active to protect or repair nervous tissue. It matters to investors because it underlies many neurological diseases and is a common target for drugs and diagnostic tools; positive or negative trial results, safety signals, or new therapies can change a company’s value much like a major repair plan or recall would affect a carmaker’s prospects.

mirna dysregulation medical

"including neuroinflammation, iron dysregulation, and miRNA dysregulation"

MicroRNA dysregulation is when tiny genetic switches called microRNAs — short pieces of RNA that help turn genes on or off — are present at the wrong amounts or at the wrong times, causing cells to behave abnormally (for example by growing, dying, or communicating improperly). It matters to investors because these imbalances can drive diseases or alter how well drugs and diagnostic tests work, influencing clinical trial success, approval risk, and the commercial prospects of biotech and healthcare companies.

phase 3 medical

"We are preparing for initiation of a Phase 3 pivotal clinical trial for PrimeC in ALS"

Phase 3 is the late-stage clinical testing step for a new drug or medical treatment, where the product is given to large groups of patients to confirm effectiveness, monitor side effects, and compare it to standard care. Successful Phase 3 results are often the final scientific hurdle before regulators decide on approval and market launch—like passing a final exam before graduation—and can sharply change a company's valuation and future revenue prospects.

phase 2b medical

"following positive Phase 2b PARADIGM results and clearance from the FDA"

Phase 2b is a stage in the development of a new medicine or treatment where researchers test its effectiveness and safety in a larger group of people. This step helps determine whether the treatment works well enough to move forward and if it has manageable side effects, which is important for investors because successful results can lead to potential approval and market opportunity.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

• Patent Protection Through October 2042
• Follows prior patent grants in the U.S. and Australia
• Further strengthens NeuroSense's global intellectual property portfolio

CAMBRIDGE, Mass., April 6, 2026 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense" or the "Company"), a late-clinical stage biotechnology company developing novel treatments for severe neurodegenerative diseases, today announced that the Brazilian Patent and Trademark Office (INPI) has granted Brazilian Patent No. BR 112024007727-6, entitled "Compositions Comprising Ciprofloxacin and Celecoxib."

 

 

The granted Brazilian patent, following prior approval of the corresponding U.S. patent (12,097,185) and Australian patent (2022370513), provides protection for NeuroSense's proprietary PrimeC composition in Brazil and extends patent coverage through October 2042, further strengthening the Company's global intellectual property estate and supporting the long-term development and potential commercialization of PrimeC in ALS, Alzheimer's disease and additional neurodegenerative indications.

"This patent grant further reinforces the strength and durability of our intellectual property strategy around PrimeC," said Alon Ben-Noon, Chief Executive Officer of NeuroSense. "Securing composition-of-matter protection in Brazil is another important step in expanding our global IP footprint as we advance PrimeC toward pivotal development and potential commercialization."

PrimeC is a proprietary fixed-dose oral therapy combining ciprofloxacin and celecoxib in a synchronized, extended-release formulation specifically targeted to deliver both agents in a coordinated manner - a key differentiator versus simple co-administration. The formulation is designed to enable consistent exposure across multiple disease pathways implicated in ALS, including neuroinflammation, iron dysregulation, and miRNA dysregulation, supporting a multi-target disease-modifying approach.

We are preparing for initiation of a Phase 3 pivotal clinical trial for PrimeC in ALS (PARAGON), following positive Phase 2b PARADIGM results and clearance from the FDA.

About NeuroSense

NeuroSense Therapeutics, Ltd. is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. NeuroSense believes that these diseases, which include amyotrophic lateral sclerosis (ALS), Alzheimer's disease and Parkinson's disease, among others, represent one of the most significant unmet medical needs of our time, with limited effective therapeutic options available for patients to date. Due to the complexity of neurodegenerative diseases and based on strong scientific research on a large panel of related biomarkers, NeuroSense's strategy is to develop combined therapies targeting multiple pathways associated with these diseases.

For additional information, we invite you to visit our website and follow us on LinkedIn, YouTube and X. Information that may be important to investors may be routinely posted on our website and these social media channels.

About PrimeC

PrimeC, NeuroSense's lead drug candidate, is a novel extended-release oral formulation composed of a unique fixed-dose combination of two FDA-approved drugs: ciprofloxacin and celecoxib. PrimeC is designed to synergistically target several key mechanisms of ALS and AD, that contribute to neuron degeneration, inflammation, iron accumulation and impaired ribonucleic acid ("RNA") regulation to potentially inhibit the progression of ALS and AD.

About ALS

Amyotrophic lateral sclerosis ("ALS") is an incurable neurodegenerative disease that causes complete paralysis and death within 2-5 years from diagnosis. Every year, more than 5,000 people are diagnosed with ALS in the U.S. alone, with an annual disease burden of $1 billion. The number of people living with ALS is expected to grow by 24% by 2040 in the U.S. and EU.

About Alzheimer's Disease
Alzheimer's disease (AD) is a progressive neurodegenerative disorder and the leading cause of dementia worldwide, affecting more than 30 million people globally. AD is characterized by memory loss, cognitive decline, and behavioral changes, and currently has no cure. Existing therapies provide only limited symptomatic relief, leaving a significant unmet need for disease-modifying treatments that can slow or halt progression. Given the complexity of AD, approaches that target multiple disease mechanisms simultaneously, such as PrimeC, hold potential to deliver meaningful therapeutic advances for patients and their families.

Forward-Looking Statements

This press release contains "forward-looking statements" that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as "anticipate," "believe," "contemplate," "could," "estimate," "expect," "intend," "seek," "may," "might," "plan," "potential," "predict," "project," "target," "aim," "should," "will" "would," or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on NeuroSense Therapeutics' current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict and include statements regarding PrimeC pivotal trial. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. The future events and trends may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward looking statements. These risks include the risk that we do not complete in a timely fashion the PrimeC pivotal trial, and that the single pivotal trial will not be sufficient to support a New Drug Application submission; uncertainty regarding the timing of regulatory filings, meetings and regulatory decisions; outcomes and the timing of current and future clinical trials; the risk the PrimeC will not advance towards later-stage development, timing for reporting data, including from the study of PrimeC in Alzheimer's disease; that the study will not be successful; the ability of NeuroSense to remain listed on Nasdaq; the going concern reference in our financial statements and our need for substantial additional financing to achieve our goals; and other risks and uncertainties set forth in NeuroSense's filings with the Securities and Exchange Commission (SEC). You should not rely on these statements as representing our views in the future. More information about the risks and uncertainties affecting NeuroSense is contained under the heading "Risk Factors" in the Annual Report on Form 20-F filed with the Securities and Exchange Commission on March 31, 2026 and NeuroSense's subsequent filings with the SEC. Forward-looking statements contained in this announcement are made as of this date, and NeuroSense undertakes no duty to update such information except as required under applicable law.

Logo: https://mma.prnewswire.com/media/1707291/NeuroSense_Therapeutics_Logo.jpg

View original content:https://www.prnewswire.com/news-releases/neurosense-granted-brazilian-patent-covering-primec-composition-302734651.html

SOURCE NeuroSense

FAQ

What patent did NeuroSense (NRSN) receive in Brazil on April 6, 2026?

NeuroSense received Brazilian Patent No. BR 112024007727-6, covering the PrimeC composition. According to the company, this grant follows related U.S. and Australian patents and extends patent protection in Brazil through October 2042.

How long does PrimeC patent protection last in Brazil for NRSN?

Patent protection for PrimeC in Brazil extends through October 2042. According to the company, the Brazilian grant aligns with corresponding U.S. and Australian patents to strengthen global IP coverage.

What is PrimeC and how is it different, per NeuroSense (NRSN)?

PrimeC is a fixed-dose oral therapy combining ciprofloxacin and celecoxib in an extended-release formulation. According to the company, it synchronizes delivery of both agents versus simple co-administration, targeting multiple ALS disease pathways.

Does the Brazilian patent affect NeuroSense's clinical plans for PrimeC (NRSN)?

The patent supports NeuroSense's long-term development and potential commercialization plans for PrimeC. According to the company, it is preparing to initiate the Phase 3 PARAGON trial after positive Phase 2b results and FDA clearance.

Which patent numbers correspond to PrimeC outside Brazil for NRSN?

Corresponding patents cited are U.S. patent 12,097,185 and Australian patent 2022370513. According to the company, these grants collectively strengthen PrimeC's global intellectual property estate.